New small molecules targeting apoptosis and cell viability in osteosarcoma

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Maugg, Doris ^a,b   Rothenaigner, Ina ^a   Schorpp, Kenji ^a   Potukuchi, Harish Kumar ^a,b   Korsching, Eberhard ^d   Baumhoer, Daniel ^a,e   Hadian, Kamyar ^a   Smida, Jan ^a,b   Nathrath, Michaela ^a,b,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KLINIKUM KASSEL   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; COMPOUND A 13; COMPOUND H 12; DOXORUBICIN; PROTEIN P53; STAUROSPORINE; UNCLASSIFIED DRUG; MOLECULAR LIBRARY;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; CELL VIABILITY; CHEMOSENSITIVITY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INDUCTION; HEPG2 CELL LINE; HIGH THROUGHPUT SCREENING; MITOCHONDRION; OSTEOBLASTOMA; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PHENOTYPE; SAOS 2 CELL LINE; U2OS CELL LINE; ANTIBODY SPECIFICITY; CELL SURVIVAL; CHEMISTRY; DEFICIENCY; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HEP-G2 CELL LINE; HUMAN; LIVER CELL; MESENCHYMAL STROMA CELL; METABOLISM; MOLECULAR LIBRARY; OSTEOBLAST; PATHOLOGY; PHARMACOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HEP G2 CELLS; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MESENCHYMAL STROMAL CELLS; ORGAN SPECIFICITY; OSTEOBLASTS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STAUROSPORINE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84934913560     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129058     Document Type: Article

References (54)

1. Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152: 3-13. doi: 10.1007/978-1-4419-0284-9-1 PMID: 20213383
2. Sampson VB, Gorlick R, Kamara D, Anders Kolb E (2013) A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol 3: 132. doi: 10.3389/fonc.2013.00132 PMID: 23755370
3. Bayani J, Zielenska M, Pandita A, Al-Romaih K, Karaskova J, et al. (2003) Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 36: 7-16. PMID: 12461745
4. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, et al. (2009) Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219: 294-305. doi: 10.1002/path.2603 PMID: 19718709
5. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al. (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27-40. doi: 10.1016/j.cell.2010.11.055 PMID: 21215367
6. Ferrari S, Palmerini E (2007) Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19: 341-346. PMID: 17545797
7. Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, et al. (2009) Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27: 557-565. doi: 10.1200/JCO.2008.16.2305 PMID: 19075282
8. van Maldegem AM, Bhosale A, Gelderblom HJ, Hogendoorn PC, Hassan AB (2012) Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. Clin Sarcoma Res 2: 5. doi: 10.1186/2045-3329-2-5 PMID: 22587841
9. Botter SM, Neri D, Fuchs B (2014) Recent advances in osteosarcoma. Curr Opin Pharmacol 16: 15-23. doi: 10.1016/j.coph.2014.02.002 PMID: 24632219
10. Cao Y, Roth M, Piperdi S, Montoya K, Sowers R, et al. (2014) Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma. PLoS One 9: e106249. doi: 10.1371/journal.pone.0106249 PMID: 25170759
11. Van Maerken T, Rihani A, Van Goethem A, De Paepe A, Speleman F, et al. (2014) Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. Cancer Lett 344: 157-165. doi: 10.1016/j.canlet.2013.11.002 PMID: 24262662
12. Shimizu T, Sugihara E, Yamaguchi-Iwai S, Tamaki S, Koyama Y, et al. (2014) IGF2 Preserves Osteosarcoma Cell Survival by Creating an Autophagic State of Dormancy That Protects Cells against Chemotherapeutic Stress. Cancer Res 74: 6531-6541. doi: 10.1158/0008-5472.CAN-14-0914 PMID: 25273088
13. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, et al. (2003) The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A 100: 11547-11552. PMID: 12972634
14. Chen X, Bahrami A, Pappo A, Easton J, Dalton J, et al. (2014) Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 7: 104-112. doi: 10.1016/j.celrep.2014.03.003 PMID: 24703847
15. Ribi S, Baumhoer D, Lee K, Edison, Teo AS, et al. (2015) TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. Oncotarget.
16. Khoo KH, Verma CS, Lane DP (2014) Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 13: 217-236. doi: 10.1038/nrd4236 PMID: 24577402
17. Fleuren ED, Versleijen-Jonkers YM, Boerman OC, van der Graaf WT (2014) Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives. Biochim Biophys Acta 1845: 266-276. doi: 10.1016/j.bbcan.2014.02.005 PMID: 24582852
18. Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, et al. (2014) Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res 20: 4200-4209. doi: 10.1158/1078-0432.CCR-13-2574 PMID: 24803583
19. Schorpp K, Rothenaigner I, Salmina E, Reinshagen J, Low T, et al. (2013) Identification of Small-Molecule Frequent Hitters from AlphaScreen High-Throughput Screens. J Biomol Screen 19: 715-726. PMID: 24371213
20. Carmody LC, Germain AR, VerPlank L, Nag PP, Munoz B, et al. (2012) Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. J Biomol Screen 17: 1204-1210. PMID: 22941295
21. Wawer MJ, Li K, Gustafsdottir SM, Ljosa V, Bodycombe NE, et al. (2014) Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling. Proc Natl Acad Sci U S A 111: 10911-10916. doi: 10.1073/pnas.1410933111 PMID: 25024206
22. Swinney DC (2013) The contribution of mechanistic understanding to phenotypic screening for first-inclass medicines. J Biomol Screen 18: 1186-1192. doi: 10.1177/1087057113501199 PMID: 23983234
23. Guerzoni C, Amatori S, Giorgi L, Manara MC, Landuzzi L, et al. (2014) An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. BMC Cancer 14: 137. doi: 10.1186/1471-2407-14-137 PMID: 24575739
24. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, et al. (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 26: 633-638. doi: 10.1200/JCO.2008.14.0095 PMID: 18235123
25. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, et al. (2010) Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49: 40-51. doi: 10.1002/gcc.20717 PMID: 19787792
26. Yen ML, Chien CC, Chiu IM, Huang HI, Chen YC, et al. (2007) Multilineage differentiation and characterization of the human fetal osteoblastic 1.19 cell line: a possible in vitro model of human mesenchymal progenitors. Stem Cells 25: 125-131. PMID: 17204605
27. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26. PMID: 11259830
28. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336. PMID: 15711537
29. Tacar O, Indumathy S, Tan ML, Baindur-Hudson S, Friedhuber AM, et al. (2014) Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: comparison with osteosarcoma cells. J Pharm Pharmacol.
30. Posthumadeboer J, van Egmond PW, Helder MN, de Menezes RX, Cleton-Jansen AM, et al. (2012) Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin. Oncotarget 3: 1169-1181. PMID: 23045411
31. Subramaniam M, Jalal SM, Rickard DJ, Harris SA, Bolander ME, et al. (2002) Further characterization of human fetal osteoblastic hFOB 1.19 and hFOB/ER alpha cells: bone formation in vivo and karyotype analysis using multicolor fluorescent in situ hybridization. J Cell Biochem 87: 9-15. PMID: 12210717
32. Thalmeier K, Meissner P, Reisbach G, Falk M, Brechtel A, et al. (1994) Establishment of two permanent human bone marrow stromal cell lines with long-term post irradiation feeder capacity. Blood 83: 1799-1807. PMID: 8142648
33. Conrad C, Zeindl-Eberhart E, Moosmann S, Nelson PJ, Bruns CJ, et al. (2008) Alkaline phosphatase, glutathione-S-transferase-P, and cofilin-1 distinguish multipotent mesenchymal stromal cell lines derived from the bone marrow versus peripheral blood. Stem Cells Dev 17: 23-27. doi: 10.1089/scd.2007.0159 PMID: 18237266
34. Fulda S (2013) Targeting apoptosis pathways in childhood malignancies. Cancer Lett 332: 369-373. doi: 10.1016/j.canlet.2010.10.003 PMID: 21036468
35. Kroemer G, Dallaporta B, Resche-Rigon M (1998) The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60: 619-642. PMID: 9558479
36. Silva MT (2010) Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett 584: 4491-4499. doi: 10.1016/j.febslet.2010.10.046 PMID: 20974143
37. Zong WX, Thompson CB (2006) Necrotic death as a cell fate. Genes Dev 20: 1-15. PMID: 16391229
38. Abraham VC, Towne DL, Waring JF, Warrior U, Burns DJ (2008) Application of a High-Content Multiparameter Cytotoxicity Assay to Prioritize Compounds Based on Toxicity Potential in Humans. Journal of Biomolecular Screening 13: 527-537. doi: 10.1177/1087057108318428 PMID: 18566484
39. Calvert RJ, Vohra S (2013) Doxorubicin-treated H9c2 cells: caution with luminescent ATP and Hoechst 33258 assays. In Vitro Cell Dev Biol Anim 49: 95-96. doi: 10.1007/s11626-012-9573-1 PMID: 23288412
40. Niles AL, Riss TL (2015) "Multiplexed viability, cytotoxicity, and caspase activity assays". Methods Mol Biol 1219: 21-33. doi: 10.1007/978-1-4939-1661-0-3 PMID: 25308259
41. Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9: 447-464. doi: 10.1038/nrd3137 PMID: 20467424
42. Ma D, Tremblay P, Mahngar K, Collins J, Hudlicky T, et al. (2011) Selective cytotoxicity against human osteosarcoma cells by a novel synthetic C-1 analogue of 7-deoxypancratistatin is potentiated by curcumin. PLoS One 6: e28780. doi: 10.1371/journal.pone.0028780 PMID: 22205968
43. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, et al. (2010) Autophagy regulation by p53. Curr Opin Cell Biol 22: 181-185. doi: 10.1016/j.ceb.2009.12.001 PMID: 20044243
44. Wan X, Mendoza A, Khanna C, Helman LJ (2005) Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65: 2406-2411. PMID: 15781656
45. Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, et al. (2014) Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A.
46. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, et al. (1994) MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 86: 1297-1302. PMID: 8064888
47. Chipoy C, Brounais B, Trichet V, Battaglia S, Berreur M, et al. (2007) Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene 26: 6653-6664. PMID: 17471233
48. Koul D, Fu J, Shen R, LaFortune TA, Wang S, et al. (2012) Antitumor activity of NVP-BKM120 - a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18: 184-195. doi: 10.1158/1078-0432.CCR-11-1558 PMID: 22065080
49. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, et al. (2010) NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16: 530-540. doi: 10.1158/1078-0432.CCR-09-0816 PMID: 20068094
50. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10: 507-519. doi: 10.1038/nrd3480 PMID: 21701501
51. Poos K, Smida J, Nathrath M, Maugg D, Baumhoer D, et al. (2013) How microRNA and transcription factor co-regulatory networks affect osteosarcoma cell proliferation. PLoS Comput Biol 9: e1003210. doi: 10.1371/journal.pcbi.1003210 PMID: 24009496
52. Baumhoer D, Zillmer S, Unger K, Rosemann M, Atkinson MJ, et al. (2012) MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer genetics 205: 212-219. doi: 10.1016/j.cancergen.2012.03.001 PMID: 22682620
53. Benjamini Y, Yosef H (1955) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289-300.
54. Sebaugh JL (2011) Guidelines for accurate EC50/IC50 estimation. Pharm Stat 10: 128-134. doi: 10.1002/pst.426 PMID: 22328315